Currently browsing: Community News

Assorted News from the Last Week: Nearly one in four families of pediatric patients with acute lymphoblastic leukemia (ALL) enrolled in a clinical trial experienced food insecurity, and almost half of the families eligible for the Supplemental Nutrition Assistance Program (SNAP) did not receive benefits. In addition, receiving SNAP benefits was not sufficient to address food insecurity. Patients who undergo radiotherapy for the treatment of childhood cancer have an increased risk of developing meningioma later in life, and that risk may persist for 30 years, according to a case-control study published in JAMA Oncology. The incidence of invasive breast cancer […]

Read more

Assorted News from the Last Week: Pedmark (sodium thiosulfate) is now available to reduce the risk of ototoxicity associated with cisplatin in pediatric patients 1 month of age and older with localized, nonmetastatic solid tumors. Pediatric patients with cancer and those who have undergone hematopoietic stem cell transplant (HSCT) may develop long-term effects, including fatigue. However, fatigue is not associated with treatment intensity or therapy type, according to findings published in the Journal of Child Health Care. Real-world costs for care for commercially insured U.S. pediatric patients with acute lymphoblastic leukemia (ALL) were higher in those diagnosed at age 10 [...] Read more

Assorted News from the Last Week: Helping kids manage fear and anxiety when they have a serious illness Public sharing of pediatric brain cancer presentation prepared for House Health Subcommittee supporting H. Res. 404 New findings show more than 32,000 newly diagnosed adolescent and young adult (AYA) cancer patients may lose or face compromised fertility preservation care each year due to legislation that has been enacted or is expected to be enacted in some states. Despite decades of medical advances, children who develop the pediatric eye cancer retinoblastoma often lose their vision or an eye due to a lack of […]

Read more

Assorted News from the Last Week: Making transformative advances against childhood cancer:  A conversation with Dr. Doug Hawkins The FDA has approved sodium thiosulfate (Pedmark) to reduce the risk of ototoxicity associated with cisplatin in pediatric patients aged 1 month and older with localized, nonmetastatic solid tumors. The White House announced its support for the Childhood Cancer STAR Reauthorization Act. Gift from a Child/Swifty highlighted on ABC News Chicago.  With further coverage here. Financial hardship in adult survivors of childhood cancer in the era after implementation of the affordable care act:  A report from the Childhood Cancer Survivor Study Upcoming Webinars, [...] Read more

Assorted News from the Last Week: The FDA has approved sodium thiosulfate (Pedmark) to reduce the risk of ototoxicity associated with cisplatin in pediatric patients aged 1 month and older with localized, nonmetastatic solid tumors. The White House announced its support for the Childhood Cancer STAR Reauthorization Act. Answers to common questions about COVID-19 vaccines in children with cancer Cancer in kids tied to prenatal exposure to high-dose folic acid and seizure meds, but no link seen among children of mothers without epilepsy. Scientists have found that group 3 and 4 medulloblastoma arise from the rhombic lip, knowledge that may […]

Read more

Assorted News from the Last Week: Supporting Children and Families Through a Cancer Diagnosis by Child Life Specialist Nicolle Bengtson. Nearly 20 years since her initial diagnosis, CAC2 Member Juanita Prada now works with children who are fighting cancer just like she did. Day One Biopharmaceuticals emerged in May to develop new drugs specifically for children with cancer. Now, as it ramps up its work, the company is making a flurry of new hires and new board appointments, including a new CEO: Jeremy Bender, Ph.D., who previously led corporate development at Gilead Sciences. Challenges burden pediatric oncologists following the peak […]

Read more

Assorted News from the Last Two Weeks: National Cancer Institute’s CCDI Molecular Characterization Initiative adds rare tumors. Study provides first in-depth look at major mix-ups in the genomic terrain of pediatric high-grade gliomas. LLS is working to change the pediatric clinical trial model. The aftermath of childhood cancer:  2000 days without Ana Biden appoints former government scientist as first leader of ARPA-H. The use of tisagenlecleucel (Kymriah) in children younger than 3 years of age with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL) was as effective, and safe, in a retrospective cohort study as it was previously seen to […]

Read more

Assorted News from the Last Two Weeks: The Food and Drug Administration (FDA) approved Imbruvica (ibrutinib) for the treatment of children aged 1 year or older with chronic graft-versus-host disease (cGVHD) after one or more lines of systemic therapy, according to a news release from the agency. FDA drug approvals, pediatrics — 2022 midyear review Guidebook for caregivers of children with rare and/or serious illnesses 10 gifts to give a friend whose child has cancer or another serious illness Researchers identified a metabolic vulnerability in neuroblastoma that could be exploited to overturn these tumors’ resistance to therapy. Millions of Americans, […]

Read more

Assorted News from the Last Week: Leukemia and Lymphoma Society’s (LLS) has launched its Dare to Dream Project as an extension of itself Children’s Initiative.  It will expand education and support services for patients and families, drives advocacy and policy efforts, and increases investments in childhood blood cancer research. Neuroblastoma cells have an extreme need for amino acids. Scientists at the Hopp Children’s Cancer Center Heidelberg (KiTZ), the German Cancer Research Center (DKFZ), the University of Heidelberg, and HI-STEM gGmbH have now discovered the molecular mechanisms underlying this and how the cancer cells could be turned off. From the Washington […]

Read more